|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
68,210,000 |
Market
Cap: |
3.22(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$20.06 - $60.2 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Merus is a clinical-stage oncology company developing antibody therapeutics. Using its Biclonics® platform, Co. has produced and is developing the following candidates: MCLA-128 (zenocutuzumab) for the treatment of solid tumors that harbor Neuregulin 1 gene fusions; MCLA-117 for the treatment of acute myeloid leukemia; MCLA-158 for the treatment of solid tumors; and MCLA-145, developed in collaboration with Incyte Corporation, for the potential treatment of solid tumors and a hematological malignancy, B-cell lymphoma. Co. is also developing a late-stage pre-clinical candidate, MCLA-129 in collaboration with Betta Pharmaceuticals Co. Ltd., for the potential treatment of solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
14,706 |
Total Buy Value |
$0 |
$0 |
$0 |
$211,431 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
15,000 |
91,300 |
114,626 |
115,944 |
Total Sell Value |
$870,000 |
$5,166,988 |
$5,749,950 |
$5,773,454 |
Total People Sold |
2 |
2 |
2 |
2 |
Total Sell Transactions |
3 |
7 |
11 |
14 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shuman Harry |
VP Controller, PAO |
|
2023-12-19 |
4 |
S |
$26.68 |
$3,068 |
D/D |
(115) |
7,002 |
|
-75% |
|
Silverman Peter B. |
COO & GC |
|
2023-12-15 |
4 |
S |
$25.00 |
$559,650 |
D/D |
(22,386) |
0 |
|
-79% |
|
Silverman Peter B. |
COO & GC |
|
2023-12-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,386 |
22,386 |
|
- |
|
Shuman Harry |
VP Controller, PAO |
|
2023-12-08 |
4 |
S |
$24.44 |
$6,110 |
D/D |
(250) |
7,117 |
|
-69% |
|
Shuman Harry |
VP Controller, PAO |
|
2023-12-01 |
4 |
AS |
$24.58 |
$14,134 |
D/D |
(575) |
7,367 |
|
67% |
|
Shuman Harry |
VP Controller, PAO |
|
2023-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
7,942 |
|
- |
|
Shuman Harry |
VP Controller, PAO |
|
2023-06-01 |
4 |
AS |
$21.48 |
$12,351 |
D/D |
(575) |
5,442 |
|
-6% |
|
Shuman Harry |
VP Controller, PAO |
|
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
6,017 |
|
- |
|
Iwicki Mark T |
Director |
|
2023-04-14 |
4 |
OE |
$6.57 |
$534,679 |
D/D |
73,576 |
73,576 |
|
- |
|
Liu Hui |
EVP, CBO & Head of Merus US |
|
2023-04-06 |
4 |
OE |
$7.86 |
$770,948 |
D/D |
98,085 |
156,016 |
|
- |
|
Shuman Harry |
VP Controller, PAO |
|
2022-12-13 |
4 |
S |
$13.85 |
$2,327 |
D/D |
(168) |
3,517 |
|
-47% |
|
Shuman Harry |
VP Controller, PAO |
|
2022-12-01 |
4 |
AS |
$15.35 |
$8,826 |
D/D |
(575) |
3,685 |
|
29% |
|
Shuman Harry |
VP Controller, PAO |
|
2022-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
4,260 |
|
- |
|
Lundberg Sven Ante |
President, CEO & PFO |
|
2022-11-03 |
4 |
AB |
$14.38 |
$211,431 |
D/D |
14,706 |
40,576 |
|
34% |
|
Shuman Harry |
VP Controller, PAO |
|
2022-08-25 |
4 |
S |
$24.33 |
$4,014 |
D/D |
(165) |
1,760 |
|
36% |
|
Lundberg Sven Ante |
President, CEO & PFO |
|
2022-08-22 |
4 |
AB |
$22.92 |
$133,558 |
D/D |
5,826 |
25,870 |
|
-32% |
|
Lundberg Sven Ante |
President, CEO & PFO |
|
2022-08-19 |
4 |
AB |
$22.99 |
$16,187 |
D/D |
704 |
20,044 |
|
-33% |
|
Lundberg Sven Ante |
President, CEO & PFO |
|
2022-07-12 |
4 |
AB |
$22.97 |
$99,685 |
D/D |
4,340 |
19,340 |
|
-31% |
|
Shuman Harry |
VP Controller, PAO |
|
2022-06-01 |
4 |
AS |
$18.31 |
$10,528 |
D/D |
(575) |
1,925 |
|
- |
|
Shuman Harry |
VP Controller, PAO |
|
2022-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
|
- |
|
Silverman Peter B. |
EVP, GC and Head of Utrecht |
|
2022-03-10 |
4 |
S |
$26.95 |
$1,617,000 |
D/D |
(60,000) |
0 |
|
- |
|
Silverman Peter B. |
EVP, GC and Head of Utrecht |
|
2022-03-10 |
4 |
OE |
$11.16 |
$669,600 |
D/D |
60,000 |
60,000 |
|
- |
|
Lampert Mark N |
10% Owner |
|
2021-10-08 |
4 |
S |
$27.79 |
$4,092,034 |
D/D |
(147,267) |
232,747 |
|
- |
|
Lampert Mark N |
10% Owner |
|
2021-10-07 |
4 |
S |
$27.53 |
$27,130,440 |
D/D |
(985,447) |
241,676 |
|
- |
|
De Kruif John |
SVP & Chief Technology Officer |
|
2021-08-12 |
4 |
AS |
$19.34 |
$53,901 |
D/D |
(2,787) |
15,282 |
|
- |
|
108 Records found
|
|
Page 1 of 5 |
|
|